These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 26851597

  • 21. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
    Bassil F, Fernagut PO, Bezard E, Meissner WG.
    Prog Neurobiol; 2014 Jul; 118():1-18. PubMed ID: 24582776
    [Abstract] [Full Text] [Related]

  • 22. The inactivation of extracellular signal-regulated kinase by glucagon-like peptide-1 contributes to neuroprotection against oxidative stress.
    Nakajima S, Numakawa T, Adachi N, Yoon HS, Odaka H, Ooshima Y, Kunugi H.
    Neurosci Lett; 2016 Mar 11; 616():105-10. PubMed ID: 26827720
    [Abstract] [Full Text] [Related]

  • 23. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases.
    Cheng D, Yang S, Zhao X, Wang G.
    Drug Des Devel Ther; 2022 Mar 11; 16():665-684. PubMed ID: 35340338
    [Abstract] [Full Text] [Related]

  • 24. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
    Hölscher C.
    Neuropharmacology; 2024 Aug 01; 253():109952. PubMed ID: 38677445
    [Abstract] [Full Text] [Related]

  • 25. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
    Elbassuoni EA, Ahmed RF.
    Neurochem Int; 2019 Dec 01; 131():104583. PubMed ID: 31654678
    [Abstract] [Full Text] [Related]

  • 26. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 27. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
    Jia Y, Gong N, Li TF, Zhu B, Wang YX.
    Pharmacol Res; 2015 Dec 29; 102():276-85. PubMed ID: 26546042
    [Abstract] [Full Text] [Related]

  • 28. Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.
    Foltynie T, Athauda D.
    Prog Brain Res; 2020 Dec 29; 252():493-523. PubMed ID: 32247373
    [Abstract] [Full Text] [Related]

  • 29. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neuronal insult: Studies in vivo and in vitro.
    An FM, Chen S, Xu Z, Yin L, Wang Y, Liu AR, Yao WB, Gao XD.
    Neuroscience; 2015 Aug 06; 300():75-84. PubMed ID: 25987199
    [Abstract] [Full Text] [Related]

  • 30. The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain.
    Bae CS, Song J.
    Int J Mol Sci; 2017 Nov 22; 18(11):. PubMed ID: 29165354
    [Abstract] [Full Text] [Related]

  • 31. Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.
    Verma A, Chaudhary S, Solanki K, Goyal A, Yadav HN.
    Chem Biol Drug Des; 2024 Jan 22; 103(1):e14426. PubMed ID: 38230775
    [Abstract] [Full Text] [Related]

  • 32. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct 22; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 33. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
    Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Plácido A, Santos MS, Oliveira CR, Moreira PI.
    Biochim Biophys Acta; 2013 Apr 22; 1832(4):527-41. PubMed ID: 23314196
    [Abstract] [Full Text] [Related]

  • 34. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS, Rhea EM, Talbot K, Banks WA.
    Biochem Pharmacol; 2020 Oct 22; 180():114187. PubMed ID: 32755557
    [Abstract] [Full Text] [Related]

  • 35. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology.
    Tramutola A, Arena A, Cini C, Butterfield DA, Barone E.
    Expert Rev Neurother; 2017 Jan 22; 17(1):59-75. PubMed ID: 27715341
    [Abstract] [Full Text] [Related]

  • 36. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
    Diz-Chaves Y, Mastoor Z, Spuch C, González-Matías LC, Mallo F.
    Int J Mol Sci; 2022 Aug 24; 23(17):. PubMed ID: 36076972
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.